Sleep, Melatonin and Childhood Atopic Dermatitis: A 72-Patient, 32-Control Study
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: This article analyzes one defined research record. The featured scene is an AI-created illustration of fictional people, not a patient, diagnosis, before-and-after image or Dr. Arsy #003 result.
The practical question
What does this study actually tell a person trying to manage school, work, sleep, movement or daily routines alongside eczema?
The threshold was derived in one study and is not a home diagnostic test or a reason to self-supplement melatonin.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 72 children with AD and 32 controls, ages 1–18 |
| Design | Cross-sectional physiologic comparison using actigraphy, polysomnography, urine and blood measures |
| Timepoint | Overnight sleep assessment with concurrent clinical severity evaluation |
| Key result | SCORAD ≥48.7 predicted poor sleep efficiency with 83.3% sensitivity and 75% specificity (AUC 0.81) |
How to read the result
SCORAD ≥48.7 predicted poor sleep efficiency with 83.3% sensitivity and 75% specificity (AUC 0.81). That estimate belongs to the stated population, design and timepoint. Prevalence, odds ratios, hazard ratios, correlations, model performance and mean differences answer different questions; none should be converted into a diagnosis or a personal forecast.
Cross-sectional data cannot show whether sleep changes severity or vice versa; age range was broad; biomarker associations are exploratory.
What can be used in real life?
Pediatric sleep problems need clinician-guided assessment; do not infer supplement dose or product suitability from this study.
A practical plan names the specific task or environment, the change being tested, the outcome to watch and when to reassess. Persistent, painful, infected, widespread or function-limiting skin problems need qualified clinical evaluation.
Primary and clinical sources
- Primary research record: PubMed PMID 25022734
- NIAMS: atopic dermatitis overview
- AAD: skin-care guidance
- NIOSH: occupational skin-exposure recommendations
PubMed indexing is not NIH endorsement of the study’s interpretation or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test it, and external findings do not become #003 efficacy claims. It is not an eczema medicine. Pediatric product questions and active disease belong with an appropriate healthcare professional.
Bottom line
The useful lesson is the narrow one: preserve the population, denominator, timepoint, result and limitations. Evidence should improve decisions without turning an association, device metric or workplace statistic into a universal promise.
Educational content only. Researchers and cited organizations do not endorse Dr. Arsy.